本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 四川科伦药业股份有限公司（以下简称"公司"）《关于公司发行非金融企 业债务融资工具的议案》已于2025年4月22日经公司第八届董事会第六次会议审 议通过，并于2025年5月19日经公司2024年年度股东大会审议批准。相关董事会 和股东大会决议公告详见2025年4月24日和2025年5月20日的《证券时报》、《上 海证券报》、《证券日报》和《中国证券报》以及公司指定信息披露网站巨潮资 讯网（http://www.cninfo.com.cn）。 2025年11月12日，公司收到中国银行间市场交易商协会（以下简称"交易商 协会"）于2025年11月11日下发的《接受注册通知书》，交易商协会同意接受公 司超短期融资券注册。具体情况如下： 证券代码：002422 证券简称：科伦药业 公告编号：2025-081 四川科伦药业股份有限公司 关于超短期融资券获准注册的公告 特此公告。 四川科伦药业股份有限公司董事会 2025 年 11 月 13 日 | 注册品种 超短期融资券 | | | | | | --- | --- | -- ...

每经AI快讯，科伦药业（002422）晚间公告，公司收到中国银行间市场交易商协会下发的《接受注册 通知书》，同意公司超短期融资券注册。注册额度为40亿，有效期为2年，主承销商为中信银行股份有 限公司。公司将根据资金需求和市场情况择机分期发行。 ...

Group 1 - The core viewpoint of the articles highlights a strong performance in the innovative drug sector, with the Medical Innovation ETF (516820.SH) rising by 1.06% and key stocks like Sangfor Technologies (688336) and Baillie Gifford (688506) showing significant gains [1] - Over the past week, the Medical Innovation ETF has seen continuous net inflows, with a peak single-day net inflow of 44.28 million yuan, totaling 78.69 million yuan and an average daily net inflow of 11.24 million yuan [1] - Recent negotiations for the 2025 National Basic Medical Insurance Drug List and commercial insurance innovative drug pricing have been completed, with 120 domestic and foreign companies participating [1] Group 2 - The recent trend in innovative drug business development (BD) is accelerating, with overseas Phase III clinical trials progressing quickly, leading to a recovery in sentiment within the innovative drug sector [1] - The industry is witnessing a positive trend in investment and financing data, orders, and performance, indicating a recovery in the innovative drug supply chain [1] - The expectation of a rate cut in the U.S. is anticipated to enhance global liquidity and support the trend in technology stocks, providing an opportunity for investors to capitalize on the rebound in core pharmaceutical assets through the Medical Innovation ETF [2]

Core Viewpoint - Kelong Pharmaceutical's stock price has shown fluctuations, with a year-to-date increase of 12.54%, but recent declines over various trading periods indicate potential volatility in investor sentiment [1][2]. Financial Performance - For the period from January to September 2025, Kelong Pharmaceutical reported a revenue of 13.277 billion yuan, representing a year-on-year decrease of 20.92%. The net profit attributable to shareholders was 1.201 billion yuan, down 51.41% year-on-year [2]. - Cumulatively, Kelong Pharmaceutical has distributed 6.898 billion yuan in dividends since its A-share listing, with 3.587 billion yuan distributed over the past three years [3]. Stock Market Activity - As of November 12, Kelong Pharmaceutical's stock was trading at 32.98 yuan per share, with a market capitalization of 52.704 billion yuan. The stock experienced a net inflow of 7.8043 million yuan from main funds [1]. - The company has appeared on the "Dragon and Tiger List" twice this year, with the most recent instance on April 30, where it recorded a net purchase of 31.8792 million yuan [1]. Shareholder Structure - As of September 30, 2025, Kelong Pharmaceutical had 37,100 shareholders, an increase of 8.35% from the previous period. The average number of circulating shares per shareholder was 35,200, a decrease of 7.70% [2]. - The top ten circulating shareholders include various funds, with notable reductions in holdings for several institutional investors [3].

Group 1 - On November 11, Kelong Pharmaceutical experienced a decline of 1.79% with a trading volume of 312 million yuan. The financing buy amount for the day was 41.75 million yuan, while the financing repayment was 13.71 million yuan, resulting in a net financing buy of 28.04 million yuan. As of November 11, the total financing and securities lending balance was 916 million yuan [1] - The financing balance of Kelong Pharmaceutical was 912 million yuan, accounting for 1.77% of the circulating market value, which is above the 60th percentile level over the past year, indicating a relatively high position [1] - In terms of securities lending, Kelong Pharmaceutical repaid 2,100 shares and sold 5,800 shares on November 11, with a selling amount of 187,500 yuan. The remaining securities lending volume was 12,000 shares, with a balance of 3.88 million yuan, also exceeding the 60th percentile level over the past year [1] Group 2 - As of September 30, Kelong Pharmaceutical had 37,100 shareholders, an increase of 8.35% compared to the previous period. The average circulating shares per person decreased by 7.70% to 35,200 shares [2] - For the period from January to September 2025, Kelong Pharmaceutical reported operating revenue of 13.28 billion yuan, a year-on-year decrease of 20.92%. The net profit attributable to the parent company was 1.20 billion yuan, down 51.41% year-on-year [2] - Kelong Pharmaceutical has distributed a total of 6.90 billion yuan in dividends since its A-share listing, with 3.59 billion yuan distributed over the past three years [2] Group 3 - As of September 30, 2025, among the top ten circulating shareholders of Kelong Pharmaceutical, China Europe Medical Health Mixed A ranked as the third-largest shareholder with 40.06 million shares, a decrease of 2.54 million shares from the previous period. Hong Kong Central Clearing Limited was the fourth-largest shareholder with 34.73 million shares, down 5.26 million shares [3] - Other notable shareholders include Guangfa Multi-Factor Mixed Fund, which remained unchanged at 24.23 million shares, and ICBC Frontier Medical Stock A, which decreased by 7.01 million shares to 20 million shares [3] - The top ten shareholders also included Huatai-PB CSI 300 ETF and E Fund CSI 300 Medical ETF, with holdings of 19.08 million shares and 14.04 million shares, respectively, both showing a decrease compared to the previous period [3]

Core Viewpoint - Kelong Pharmaceutical's stock has experienced a decline of 2.04% on November 11, with a current price of 32.25 CNY per share and a total market capitalization of 51.537 billion CNY. The company has seen a year-to-date stock price increase of 10.05%, but has faced recent declines over various trading periods [1][2]. Financial Performance - For the period from January to September 2025, Kelong Pharmaceutical reported a revenue of 13.277 billion CNY, representing a year-on-year decrease of 20.92%. The net profit attributable to shareholders was 1.201 billion CNY, down 51.41% compared to the previous year [2]. - Cumulatively, Kelong Pharmaceutical has distributed a total of 6.898 billion CNY in dividends since its A-share listing, with 3.587 billion CNY distributed over the last three years [3]. Shareholder Information - As of September 30, 2025, Kelong Pharmaceutical had 37,100 shareholders, an increase of 8.35% from the previous period. The average number of circulating shares per shareholder decreased by 7.70% to 35,200 shares [2]. - The top ten circulating shareholders include notable funds such as China Europe Medical Health Mixed A and Hong Kong Central Clearing Limited, with several shareholders reducing their holdings compared to the previous period [3]. Stock Market Activity - Kelong Pharmaceutical has appeared on the stock market's "Dragon and Tiger List" twice this year, with the most recent instance on April 30, where it recorded a net purchase of 318.792 million CNY [1]. - The stock has seen a trading volume of 171 million CNY on the day of the report, with a turnover rate of 0.40% [1]. Business Overview - Kelong Pharmaceutical, established on May 29, 2002, and listed on June 3, 2010, is primarily engaged in the development, production, and sales of large-volume infusion products. The revenue composition includes 48.37% from non-infusion products, 41.28% from infusion products, 7.01% from research projects, and 3.33% from other sources [1]. - The company operates within the pharmaceutical and biotechnology sector, specifically in chemical pharmaceuticals and formulations, and is involved in various concepts such as anesthesia, generic drugs, and innovative drugs [2].

Core Viewpoint - The Medical Health R Index (480016) closed at 7535.01 points, down 0.39%, with a trading volume of 21.869 billion yuan and a turnover rate of 0.89% on November 7 [1] Group 1: Index Performance - The index had 26 stocks rising, with Xinhecheng leading at a 4.9% increase, while 23 stocks fell, with Zaiqing Pharmaceutical leading the decline at 4.35% [1] - The top ten constituent stocks of the Medical Health R Index are primarily in the pharmaceutical and medical sectors, with notable weights and market capitalizations [1] Group 2: Key Constituents - WuXi AppTec (sh603259) holds a weight of 13.66% with a market cap of 282.98 billion yuan, closing at 94.84 yuan, down 0.89% [1] - Hengrui Medicine (sh600276) has an 11.00% weight, a market cap of 408.72 billion yuan, and closed at 61.58 yuan, down 1.35% [1] - Mindray Medical (sz300760) has a weight of 7.57%, a market cap of 249.51 billion yuan, and closed at 205.79 yuan, down 0.27% [1] - Other notable constituents include United Imaging Healthcare (sh688271), Pianzai Shou (sh600436), and Xinhecheng (sz002001), which saw a 4.9% increase [1] Group 3: Capital Flow - The Medical Health R Index constituents experienced a net outflow of 240 million yuan from institutional investors and 119 million yuan from retail investors, while retail investors saw a net inflow of 359 million yuan [1] - Specific stocks like Huazhong Pharmaceutical (000999) and Yuyue Medical (002223) showed significant net inflows and outflows among different investor types [2]

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical sector, specifically recommending the innovative drug and medical device industry chain [5][10]. Core Insights - The pharmaceutical sector shows a positive recovery trend in Q3 2025, with overall revenue growth of 0.6% year-on-year and a net profit increase of 0.3% year-on-year. This indicates a return to growth after previous declines [6][13]. - Specific segments such as medical devices and medical research outsourcing are experiencing significant growth, with revenue and net profit growth rates of 10.6% and 0.6% for medical devices, and 10.9% and 47.9% for medical research outsourcing, respectively [13][14]. - The report highlights a continued recommendation for specific A-share and H-share stocks, including 恒瑞医药 (Hengrui Medicine), 科伦药业 (Kelun Pharmaceutical), and others, indicating strong potential for investment [7][10]. Summary by Sections 1. Continued Recommendation for Innovative Drug and Medical Device Industry Chain - The report continues to recommend the innovative drug and medical device industry chain, maintaining "Overweight" ratings for several A-share stocks including 恒瑞医药, 科伦药业, and others, and H-share stocks like 翰森制药 and 三生制药 [7][10]. 2. Recovery Trend in Pharmaceutical Sector Q3 2025 - The pharmaceutical sector's overall revenue increased by 0.6% year-on-year in Q3 2025, with net profit rising by 0.3%. Medical devices and medical research outsourcing are leading this recovery with notable growth rates [13][14]. 3. Performance of Pharmaceutical Sector in October 2025 - In October 2025, the pharmaceutical sector underperformed compared to the broader market, with the SW pharmaceutical index declining by 1.8% while the Shanghai Composite Index rose by 1.9% [15][26]. 4. Performance of Hong Kong and US Pharmaceutical Sectors - The Hong Kong pharmaceutical sector also underperformed, with the Hang Seng Healthcare index down by 11.1%, while the US pharmaceutical sector showed strength with a 3.5% increase in the S&P healthcare index [26][27]. 5. Valuation and Premium Levels - As of October 31, 2025, the pharmaceutical sector's premium level relative to all A-shares is at a normal level, with a current relative premium rate of 76.7% [25][28].

Core Insights - The "2025 Sichuan Top 100 Private Enterprises" list was released, with Tongwei Group ranking first for the first time [1] - Significant changes in rankings were noted compared to the 2024 list, with Tongwei Group's revenue exceeding 240 billion yuan, moving up one position [1][2] - The threshold for entry into the list was set at 3.945 billion yuan, an increase of nearly 200 million yuan from the previous year [2] Group 1: Rankings and Revenue - The top 10 companies in the 2025 list include Tongwei Group, Qiya Group, New Hope Liuhe, Sichuan Chuanwei Group, and others [1] - The total revenue of private enterprises reached 1.74 trillion yuan, with 61 companies experiencing revenue growth [2] - The net profit of private enterprises totaled 52.04 billion yuan, with 43 companies increasing their net profit [2] Group 2: Manufacturing Sector - Manufacturing is the main support for the top 100 enterprises, with 73 companies in this sector, contributing 1.39 trillion yuan in revenue, accounting for 80.3% of the total [5] - The total assets of manufacturing enterprises also reached 1.39 trillion yuan, representing 79.3% of the total, with a significant increase of 16.4% from the previous year [5] - Tax contributions from manufacturing enterprises amounted to 45.668 billion yuan, making up 83.4% of the total [5] Group 3: Additional Rankings - The top 10 companies in the 2025 Sichuan Manufacturing Private Enterprises list mirror the top 10 of the overall list [5] - The top 10 companies in the 2025 Sichuan Service Industry Private Enterprises list include Chengdu JD Century Trading and others [6] - The top 10 companies in the 2025 Sichuan Private Enterprises R&D Investment list feature Tongwei Group and several pharmaceutical companies [6] Group 4: Economic Impact - Sichuan's GDP ranked fifth nationally, with the private economy contributing significantly, accounting for 56.4% of the total economic output [7] - The added value of the private economy reached 3.646 trillion yuan, reflecting a slight increase from the previous year [7]

Investment Rating - The report maintains a focus on innovative pharmaceuticals and medical devices, highlighting key A-share and H-share targets for investment [6][32]. Core Insights - The pharmaceutical sector showed a good recovery in Q3 2025, with overall revenue increasing by 0.6% year-on-year and net profit attributable to shareholders rising by 0.3% year-on-year [11][32]. - Medical equipment benefited from procurement recovery, with Q3 revenue and net profit growth of 10.6% and 0.6% year-on-year, respectively [11][32]. - Medical R&D outsourcing continued to achieve high growth, with Q3 revenue and net profit growth of 10.9% and 47.9% year-on-year [11][32]. - The offline pharmacy sector improved, with Q3 revenue and net profit growth of 2.1% and 37.8% year-on-year [11][32]. Summary by Sections 1. Focus on Innovative Pharmaceuticals and Medical Devices - Key A-share targets include Jiangsu Heng Rui Medicine, Sichuan Kelun Pharmaceutical, Huadong Medicine, Changchun High-tech Industry, Jiangsu Nhwa Pharmaceutical, WuXi AppTec, Hangzhou Tigermed Consulting, Lepu Medical, APT Medical, and related target Guangdong Zhongsheng Pharmaceutical [6][32]. - Key H-share targets include Hansoh Pharmaceutical Group, 3SBio, Akeso, and related target Innovent Biologics, WuXi AppTec [6][32]. 2. Q3 2025 Pharmaceutical Sector Recovery - The pharmaceutical sector's overall revenue increased by 0.6% year-on-year, with net profit attributable to shareholders up by 0.3% year-on-year [11][32]. - Specific segments such as medical devices and medical R&D outsourcing showed significant growth [11][32]. 3. October 2025 Market Performance - In October 2025, the pharmaceutical sector underperformed the market, with the SW Pharmaceutical and Biological index falling by 1.8% while the SHCOMP rose by 1.9% [14][32]. - The relative premium of the pharmaceutical sector compared to all A-shares was at a normal level, with a current relative premium rate of 76.7% [23][32]. 4. Hong Kong and U.S. Market Performance - The Hong Kong pharmaceutical sector underperformed, with the Hang Seng Healthcare index falling by 11.1% [24][32]. - In contrast, the U.S. S&P 500 healthcare sector rose by 3.5% [24][32].